George F. Tidmarsh, MD, PhD | President, Chief Executive Officer and Secretary
Dr. Tidmarsh has been President, Chief Executive Officer, Secretary and a Director of La Jolla since January 2012. Dr. Tidmarsh has over 25 years of experience in biotechnology, including the successful clinical development of three FDA-approved drugs. Prior to joining La Jolla, he served as the Chief Executive Officer of Horizon Pharma, Inc., a company he founded in 2005. While at Horizon, he led all aspects of development of Duexis, which was approved by the FDA for the treatment of rheumatoid arthritis. He also founded Threshold Pharmaceuticals, Inc. and held senior positions at Coulter Pharmaceutical, Inc. (acquired by GlaxoSmithKline) and SEQUUS Pharmaceuticals, Inc. (acquired by Johnson & Johnson). While at Coulter and SEQUUS, Dr. Tidmarsh led the clinical development of BEXXAR and Doxil, respectively, two FDA-approved anti-cancer agents. Dr. Tidmarsh received his M.D. and Ph.D. from Stanford University, where he also completed fellowship training in Pediatric Oncology and Neonatology and remains a Consulting Professor of Pediatrics and Neonatology.
Lakhmir S. Chawla, MD | Chief Medical Officer
Dr. Chawla joined La Jolla as Chief Medical Officer, effective July 1, 2015. Previously, Dr. Chawla was a Professor of Medicine at the George Washington University, where he had dual appointments in the Department of Anesthesiology and Critical Care Medicine and in the Department of Medicine, Division of Renal Diseases and Hypertension. Dr. Chawla was also the Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center. During his tenure at George Washington, Dr. Chawla was the designer and lead investigator of a pilot study called the ATHOS (Angiotensin II for the Treatment of High Output Shock) trial. Data from the ATHOS trial was published in the medical journal Critical Care during 2014 and demonstrated the utility of angiotensin II in patients with severe shock. These data were also used in support of the initiation of La Jolla’s ATHOS 3 trial, a Phase 3 clinical trial of LJPC-501, La Jolla’s proprietary formulation of angiotensin II, for the treatment of catecholamine-resistant hypotension, which was initiated in March 2015. Dr. Chawla is an internationally renowned expert in the field of acute kidney injury (AKI) and was an active investigator in the fields of inflammation and AKI, AKI biomarkers, AKI risk prediction, chronic kidney disease caused by AKI and AKI therapeutics. In addition, Dr. Chawla was an active investigator in shock, inflammation and extracorporeal therapies, including: continuous renal replacement therapy, dialysis and albumin dialysis. Dr. Chawla is also the author of over 100 peer-reviewed publications and was previously an Associate Editor for the Clinical Journal of the American Society of Nephrology.
Dennis M. Mulroy | Chief Financial Officer
Mr. Mulroy has been the Chief Financial Officer of La Jolla since April 2015. Prior to joining La Jolla, Mr. Mulroy served as Chief Financial Officer of Taxus Cardium Pharmaceuticals Group Inc., a publicly traded biotechnology company, since 2005. Prior to joining Taxus Cardium, Mr. Mulroy served as Chief Financial Officer of Molecular Imaging, Inc. and SeraCare Life Sciences, Inc., and held financial management positions of increasing responsibility at several other companies. Mr. Mulroy began his career as a Certified Public Accountant with Ernst & Young LLP in San Diego and holds a degree in Business Administration, with an emphasis in Accounting, from the University of San Diego.
Jennifer A. Carver, MBA | Chief Operating Officer
Ms. Carver has held the position of Senior VP of Operations for La Jolla since January 2016 and has broad operational responsibility for business development, clinical operations, regulatory affairs, pharmaceutical operations, legal operations, project management, information technology, and quality. She joined La Jolla in February 2014 as Sr. Director of Project Management with the purpose of establishing a project team structure for the rapidly growing company. Ms. Carver was promoted to VP of Project Management in December 2014 and then promoted to VP of Operations in June 2015. Ms. Carver has over 20 years of experience in the healthcare industry and with experienced cross-functional leadership in pharmaceutical drug development from early development through commercialization. Prior to joining La Jolla, Ms. Carver was Senior Director of Project Management at Spectrum Pharmaceuticals, Inc., leading the NDA and launch activities for Beleodaq, an FDA-approved anti-cancer agent. Previously, she held various roles at Allos Therapeutics, Inc., including project manager for Folotyn, an FDA-approved anti-cancer agent, and leading integration activities following the acquisition of Allos by Spectrum Pharmaceuticals in 2012. Ms. Carver earned her B.S.N. and M.B.A. from the University of Colorado.
James M. Rolke | Chief Scientific Officer
Mr. Rolke has been the Vice President of Research & Development of La Jolla since January 2012. Mr. Rolke has over 20 years of experience in the biotechnology industry. Prior to joining La Jolla, Mr. Rolke held several key positions at biotechnology companies, including Chief Technology Officer at Pluromed, Inc. (acquired by Sanofi), Director of Operations at Prospect Therapeutics, Inc., Associate Director of Pharmaceutical Development at Mersana Therapeutics, Inc., Manager of Process Development at GlycoGenesys, Inc., Principal Scientist at Surgical Sealants, Inc., Scientist at GelTex, Inc., and Associate Scientist at Alpha-Beta Technology, Inc. Mr. Rolke received his B.S. in chemistry from Keene State College.
Jeffrey J. Jensen | Vice President of Global Clinical Operations
Mr. Jensen joined La Jolla in March of 2016 as Vice President of Global Clinical Operations. He has over 30 years of experience in drug development at biotech, pharmaceutical and contract research companies in the US and Europe. Previously he was a Vice President of Clinical Operations and Clinical Lead at Pfizer, and held senior positions at Thesan, Metabasis, Excaliard, Quintiles, PPD, and INC Research. He specializes in managing global teams across several therapeutic areas and leading partnerships with research investigators and contract research organizations.
James A. Wilkie | Vice President of New Enterprise Development
Mr. Wilkie has been the Vice President of Pharmaceutical Operations of La Jolla since July 2014. Mr. Wilkie has over 29 years of experience in the life sciences industry. Prior to joining La Jolla, Mr. Wilkie served as Chief Operating Officer of Pluromed, Inc., until the sale of the company in 2012 to Genzyme Corporation. Mr. Wilkie joined Pluromed as Vice President of Operations in 2005 and was the first employee. He led the development team to commercialize two successful products in the U.S. and Europe, where he was responsible for the overall operation, including product development, clinical affairs, RA/QA, manufacturing, distribution and administration. Prior to his experience at Pluromed, Mr. Wilkie held various positions of increasing responsibility at MedChem Products, Inc., including Director of Engineering for 3 sites. Upon the sale of MedChem to C. R. Bard, he spun-off certain technology and co-founded Surgical Sealants, Inc. He holds 2 issued patents and several pending applications. Mr. Wilkie received his B.S. in Engineering from the University of Massachusetts.